Morgan Stanley Reiterates Underweight on Incyte, Maintains $74 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit has reiterated an Underweight rating on Incyte (NASDAQ:INCY) and maintained a $74 price target.
July 20, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has reiterated an Underweight rating on Incyte, maintaining a $74 price target.
The Underweight rating from Morgan Stanley suggests that they expect Incyte's stock to underperform compared to other stocks. This could potentially lead to a decrease in Incyte's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100